Untangling the web of systemic autoinflammatory diseases

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Rigante, Donato ^a   Lopalco, Giuseppe ^b   Vitale, Antonio ^c   Lucherini, Orso Maria ^c   Caso, Francesco ^c   De Clemente, Caterina ^c   Molinaro, Francesco ^d   Messina, Mario ^d   Costa, Luisa ^e   Atteno, Mariangela ^e   Laghi Pasini, Franco ^d   Lapadula, Giovanni ^b   Galeazzi, Mauro ^c   Iannone, Florenzo ^b   Cantarini, Luca ^c  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOINFLAMMATORY DISEASE; BLAU SYNDROME; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CINCA SYNDROME; DEFICIENCY OF THE IL 1 RECEPTOR ANTAGONIST; FAMILIAL MEDITERRANEAN FEVER; HEREDITARY PERIODIC FEVER; HYPERTRICHOSIS; INSULIN DEPENDENT DIABETES MELLITUS; MAJEED SYNDROME; METABOLIC DISORDER; MEVALONATE KINASE DEFICIENCY; NONAUTOIMMUNE INSULIN DEPENDENT DIABETES MELLITUS SYNDROME; PAPA SYNDROME; PIGMENT DISORDER; PIGMENTARY HYPERTRICHOSIS; PRIORITY JOURNAL; PROTEASOME ASSOCIATED DISORDER; PYOGENIC AUTOINFLAMMATORY DISEASE; REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ANIMAL; AUTOIMMUNE DISEASE; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM;

CYTOKINE; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922078086     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/948154     Document Type: Review

References (139)

1. M. Lamkanfi, L. V. Walle, and T.-D. Kanneganti, "Deregulated inflammasome signaling in disease, " Immunological Reviews, vol. 243, no. 1, pp. 163-173, 2011.
2. J. P. H. Drenth and J. W. M. Van Der Meer, "The inflammasome-a linebacker of innate defense, " New England Journal of Medicine, vol. 355, no. 7, pp. 730-732, 2006.
3. L. Obici and G. Merlini, "Amyloidosis in autoinflammatory syndromes, " Autoimmunity Reviews, vol. 12, no. 1, pp. 14-17, 2012.
4. S. L. Masters, A. Simon, I. Aksentijevich, and D. L. Kastner, "Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease, " Annual Review of Immunology, vol. 27, pp. 621-668, 2009.
5. M. Lidar and A. Livneh, "Familialmediterranean fever: clinical, molecular and management advancements, " Netherlands Journal of Medicine, vol. 65, no. 9, pp. 318-324, 2007.
6. H. A. Majeed, H. M. Shahin, and K. Ghandour, "The acute scrotum in Arab children with familial Mediterranean fever, " Pediatric Surgery International, vol. 16, no. 1-2, pp. 72-74, 2000.
7. S. Ozen, E. Demirkaya, G. Amaryan et al. , "Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of amonogenic disease in children, " Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 662-667, 2014.
8. K. Senel, M. A. Melikoglu, T. Baykal, M. Melikoglu, A. Erdal, and M. Ugur, "Protracted febrile myalgia syndrome in familial Mediterranean fever, " Modern Rheumatology, vol. 20, no. 4, pp. 410-412, 2010.
9. E. Sohar, J. Gafni, M. Pras, and H. Heller, "Familial Mediterranean fever. A survey of 470 cases and review of the literature, " The American Journal of Medicine, vol. 43, no. 2, pp. 227-253, 1967.
10. L. Cantarini, P. L. Capecchi, O. M. Lucherini, F. Laghi Pasini, and M. Galeazzi, "FamilialMediterranean fever diagnosed in an elderly patient, " Clinical and Experimental Rheumatology, vol. 28, no. 4, supplement 60, p. S91, 2010.
11. M. Sayarlioglu, A. Cefle, M. Inanc et al. , "Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases, " International Journal of Clinical Practice, vol. 59, no. 2, pp. 202-205, 2005.
12. A. Livneh, P. Langevitz, D. Zemer et al. , "Criteria for the diagnosis of familial Mediterranean fever, " Arthritis and Rheumatism, vol. 40, no. 10, pp. 1879-1885, 1997.
13. A. Ece, E. Cakmak, U. Uluca et al. , "The MEFV mutations and their clinical correlations in children with familialMediterranean fever in southeast Turkey, " Rheumatology International, vol. 32, no. 2, pp. 207-212, 2014.
14. G. Grateau, C. Pecheux, C. Cazeneuve et al. , "Clinical versus genetic diagnosis of familial Mediterranean fever, " Oxford Journals Medicine, vol. 93, no. 4, pp. 223-229, 2000.
15. C. Cazeneuve, Z. Hovannesyan, D. Genevieve et al. , "Familial Mediterranean fever among patients from Karabakh and the diagnostic value ofMEFV gene analysis in all classically affected populations, " Arthritis and Rheumatism, vol. 48, no. 8, pp. 2324-2331, 2003.
16. M. G. Booty, J. C. Jae, S. L. Masters et al. , "Familial Mediterranean fever with a single MEFVmutation: where is the second hit?" Arthritis and Rheumatism, vol. 60, no. 6, pp. 1851-1861, 2009.
17. D. R. Booth, J. D. Gillmore, H. J. Lachmann et al. , "The genetic basis of autosomal dominant familial Mediterranean fever, " Oxford Journals Medicine, vol. 93, no. 4, pp. 217-221, 2000.
18. D. Rigante, I. La Torraca, L. Avallone, A. L. Pugliese, S. Gaspari, and A. Stabile, "The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever, " European Review forMedical and Pharmacological Sciences, vol. 10, no. 4, pp. 173-178, 2006.
19. E. Ben-Chetrit and M. Levy, "FamilialMediterranean fever, "The Lancet, vol. 351, no. 9103, pp. 659-664, 1998.
20. E. Ben-Chetrit, S. Bergmann, and R. Sood, "Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis, " Rheumatology, vol. 45, no. 3, pp. 274-282, 2006.
21. N. T. Haar, H. Lachmann, S. Ozen et al. , "Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review, " Annals of the Rheumatic Diseases, vol. 72, no. 5, pp. 678-685, 2013.
22. A. Vitale, D. Rigante, O. M. Lucherini et al. , "Biological treatments: new weapons in the management of monogenic autoinflammatory disorders, " Mediators of Inflammation, vol. 2013, Article ID 939847, 16 pages, 2013.
23. O. Steichen, J. Van Der Hilst, A. Simon, L. Cuisset, and G. Grateau, "A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever, " Journal of Rheumatology, vol. 36, no. 8, pp. 1677-1681, 2009.
24. J. C. H. Van Der Hilst, E. J. Bodar, K. S. Barron et al. , "Longterm follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome, " Medicine, vol. 87, no. 6, pp. 301-310, 2008.
25. D. Rigante, E. Capoluongo, B. Bertoni et al. , "First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome, " Arthritis and Rheumatism, vol. 56, no. 2, pp. 658-661, 2007.
26. A. M. Siemiatkowska, L. I. van den Born, P. M. van Hagen et al. , "Mutations in the mevalonate kinase (MVK) gene cause nonsyndromic retinitis pigmentosa, " Ophthalmology, vol. 120, no. 12, pp. 2697-2705, 2013.
27. S.-Q. Zhang, T. Jiang, M. Li et al. , "Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis, " Nature Genetics, vol. 44, no. 10, pp. 1156-1160, 2012.
28. L. Cantarini, D. Rigante, M. G. Brizi et al. , "Clinical and biochemical landmarks in systemic autoinflammatory diseases, " Annals of Medicine, vol. 44, no. 7, pp. 664-673, 2012.
29. D. Rigante, "The fresco of autoinflammatory diseases from the pediatric perspective, " Autoimmunity Reviews, vol. 11, no. 5, pp. 348-356, 2012.
30. B. Bader-Meunier, B. Florkin, J. Sibilia et al. , "Mevalonate kinase deficiency: a survey of 50 patients, " Pediatrics, vol. 128, no. 1, pp. e152-e159, 2011.
31. L. Cantarini, A. Vitale, F. Magnotti, O. M. Lucherini, F. Caso, B. Frediani et al. , "Weekly oral alendronate in mevalonate kinase deficiency, " Orphanet Journal of Rare Diseases, vol. 8, no. 196, 2013.
32. C. Dode, M. Andre, T. Bienvenu et al. , "The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome, " Arthritis and Rheumatism, vol. 46, no. 8, pp. 2181-2188, 2002.
33. D. Rigante, B. Frediani, M. Galeazzi, and L. Cantarini, "Fromthe mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases, " BioMed Research International, vol. 2013, Article ID 485103, 8 pages, 2013.
34. S. Trost and C. D. Rose, "Myocarditis and sacroiliitis: 2 Previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome, " Journal of Rheumatology, vol. 32, no. 1, pp. 175-177, 2005.
35. R. Schmaltz, T. Vogt, and J. Reichrath, "Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS), "Dermato-Endocrinology, vol. 2, no. 1, pp. 26-29, 2010.
36. D. Tchernitchko, M. Chiminqgi, F. Galacteros et al. , "Unexpected high frequency of P46L TNFRSF1A allele in sub-SaharaWest African populations, " European Journal of Human Genetics, vol. 13, no. 4, pp. 513-515, 2005.
37. L. Cantarini, O. M. Lucherini, R. Cimaz, and M. Galeazzi, "Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment, " Clinical and Experimental Rheumatology, vol. 28, no. 5, p. 802, 2010.
38. L. Cantarini, O. M. Lucherini, A. Brucato et al. , "Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study, " Clinical Research in Cardiology, vol. 101, no. 7, pp. 525-531, 2012.
39. L. Cantarini, O. M. Lucherini, C. T. Baldari, F. Laghi Pasini, and M. Galeazzi, "Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome, " Clinical and Experimental Rheumatology, vol. 28, no. 3, pp. 405-407, 2010.
40. L. Cantarini, O. M. Lucherini, R. Cimaz et al. , "Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome, " International Journal of Immunopathology and Pharmacology, vol. 22, no. 4, pp. 1051-1058, 2009.
41. L. Cantarini, O. M. Lucherini, F. Iacoponi et al. , "Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders, " International Journal of Immunopathology and Pharmacology, vol. 23, no. 4, pp. 1133-1141, 2010.
42. L. Cantarini, F. Iacoponi, O. M. Lucherini et al. , "Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults, " International Journal of Immunopathology and Pharmacology, vol. 24, no. 3, pp. 695-702, 2011.
43. F. Magnotti, A. Vitale, D. Rigante et al. , "The most recent advances in pathophysiology and management of tumour necrosis factor receptor associated periodic syndrome (TRAPS): personal experience and literature review, " Clinical and Experimental Rheumatology, vol. 31, no. 3, supplement 77, pp. 141-149, 2013.
44. S. Chia, M. Qadan, R. Newton, C. A. Ludlam, K. A. A. Fox, and D. E. Newby, "Intra-arterial tumor necrosis factor-α impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 4, pp. 695-701, 2003.
45. S. Stojanov, C. Dejaco, P. Lohse et al. , "Clinical and functional characterisation of a novel TNFRSF1A c. 605TA/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment, " Annals of the Rheumatic Diseases, vol. 67, no. 9, pp. 1292-1298, 2008.
46. F. C. Kimberley, A. A. Lobito, R. M. Siegel, and G. R. Screaton, "Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome, " Arthritis Research and Therapy, vol. 9, no. 4, article 217, 2007.
47. A. Caminero, M. Comabella, and X. Montalban, "Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis, " Clinical and Experimental Immunology, vol. 166, no. 3, pp. 338-345, 2011.
48. Z. Amoura, C. Dode, S. Hue et al. , "Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease, " Arthritis and Rheumatism, vol. 52, no. 2, pp. 608-611, 2005.
49. K. M. Hull, E. Drewe, I. Aksentijevich et al. , "The TNF receptorassociated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder, " Medicine, vol. 81, no. 5, pp. 349-368, 2002.
50. M. F. McDermott, I. Aksentijevich, J. Galon et al. , "Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes, " Cell, vol. 97, no. 1, pp. 133-144, 1999.
51. E. Aganna, P. N. Hawkins, S. Ozen et al. , "Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis, " Genes and Immunity, vol. 5, no. 4, pp. 289-293, 2004.
52. L. Cantarini, D. Rigante, O. M. Lucherini et al. , "Role of etanercept in the treatment of tumor necrosis factor receptorassociated periodic syndrome: personal experience and review of the literature, " International Journal of Immunopathology and Pharmacology, vol. 23, no. 3, pp. 701-707, 2010.
53. M. Gattorno, M. A. Pelagatti, A. Meini et al. , "Persistent efficacy of anakinra in patients with tumor necrosis factor receptorassociated periodic syndrome, " Arthritis and Rheumatism, vol. 58, no. 5, pp. 1516-1520, 2008.
54. E. Drewe, R. J. Powell, and E. M. Mcdermott, "Comment on: failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS), " Rheumatology, vol. 46, no. 12, pp. 1865-1866, 2007.
55. B. Nedjai, G. A. Hitman, N. Quillinan et al. , "Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome, " Arthritis and Rheumatism, vol. 60, no. 2, pp. 619-625, 2009.
56. M. G. Brizi, M. Galeazzi, O. M. Lucherini, L. Cantarini, and R. Cimaz, "Successful treatment of tumor necrosis factor receptorassociated periodic syndrome with canakinumab, " Annals of Internal Medicine, vol. 156, no. 12, pp. 907-908, 2012.
57. J. R. Yu and K. S. Leslie, "Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response, " Current Allergy and Asthma Reports, vol. 11, no. 1, pp. 12-20, 2011.
58. L. Cantarini, O. M. Lucherini, B. Frediani et al. , "Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes, " International Journal of Immunopathology and Pharmacology, vol. 24, no. 4, pp. 827-836, 2011.
59. R. Goldbach-Mansky, N. J. Dailey, S. W. Canna et al. , "Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition, " New England Journal of Medicine, vol. 355, no. 6, pp. 581-592, 2006.
60. B. Neven, I. Callebaut, A.-M. Prieur et al. , "Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU, " Blood, vol. 103, no. 7, pp. 2809-2815, 2004.
61. A. Vitale, O. M. Lucherini, M. Galeazzi, B. Frediani, and L. Cantarini, "Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series, " Clinical and Experimental Rheumatology, vol. 30, no. 6, pp. 943-946, 2012.
62. L. Agostini, F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp, "NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder, " Immunity, vol. 20, no. 3, pp. 319-325, 2004.
63. D. Rigante, V. Ansuini, M. Caldarelli, B. Bertoni, I. La Torraca, and A. Stabile, "Hydrocephalus in CINCA syndrome treated with anakinra, " Child's Nervous System, vol. 22, no. 4, pp. 334-337, 2006.
64. R. Goldbach-Mansky, "Current status of understanding the pathogenesis and management of patients with NOMID/ CINCA, " Current Rheumatology Reports, vol. 13, no. 2, pp. 123-131, 2011.
65. K. L. Williams, J. D. Lich, J. A. Duncan et al. , "The CATERPILLER protein Monarch-1 is an antagonist of tolllike receptor-, tumor necrosis factor α-, and Mycobacterium tuberculosis-induced pro-inflammatory signals, " Journal of Biological Chemistry, vol. 280, no. 48, pp. 39914-39924, 2005.
66. G. Bonizzi and M. Karin, "The two NF-αB activation pathways and their role in innate and adaptive immunity, " Trends in Immunology, vol. 25, no. 6, pp. 280-288, 2004.
67. S. Borghini, S. Tassi, S. Chiesa et al. , "Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation, " Arthritis and Rheumatism, vol. 63, no. 3, pp. 830-839, 2011.
68. I. Jeru, P. Duquesnoy, T. Fernandes-Alnemri et al. , "Mutations in NALP12 cause hereditary periodic fever syndromes, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1614-1619, 2008.
69. I. Jeru, V. Hentgen, S. Normand et al. , "Role of interleukin-1β in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy, "Arthritis and Rheumatism, vol. 63, no. 7, pp. 2142-2148, 2011.
70. E. B. Blau, "Familial granulomatous arthritis, iritis, and rash, " Journal of Pediatrics, vol. 107, no. 5, pp. 689-693, 1985.
71. J. Cavanaugh, "NOD2: ethnic and geographic differences, " World Journal of Gastroenterology, vol. 12, no. 23, pp. 3673-3677, 2006.
72. C. Miceli-Richard, S. Lesage, M. Rybojad et al. , "CARD15 mutations in Blau syndrome, " Nature Genetics, vol. 29, no. 1, pp. 19-20, 2001.
73. N. Kanazawa, I. Okafuji, N. Kambe et al. , "Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-αB activation: common genetic etiology with Blau syndrome, " Blood, vol. 105, no. 3, pp. 1195-1197, 2005.
74. C. D. Rose, T. M. Doyle, G. McIlvain-Simpson et al. , "Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis, " Journal of Rheumatology, vol. 32, no. 2, pp. 373-375, 2005.
75. B. A. Rybicki, M. J. Maliarik, C. H. Bock et al. , "The Blau syndrome gene is not a major risk factor for sarcoidosis, " Sarcoidosis Vasculitis and Diffuse Lung Disease, vol. 16, no. 2, pp. 203-208, 1999.
76. X. Wang, H. Kuivaniemi, G. Bonavita et al. , "CARD15 mutations in familial granulomatosis syndromes: a study of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy, "Arthritis and Rheumatism, vol. 46, no. 11, pp. 3041-3045, 2002.
77. M. L. Becker and C. D. Rose, "Blau syndrome andrelatedgenetic disorders causing childhood arthritis, " Current rheumatology reports, vol. 7, no. 6, pp. 427-433, 2005.
78. N. Milman, K. Ursin, E. ROdevand, F. C. Nielsen, and T. V. O. Hansen, "A novel mutation in the NOD2 gene associated with Blau syndrome a Norwegian family with four affected members, " Scandinavian Journal of Rheumatology, vol. 38, no. 3, pp. 190-197, 2009.
79. C. D. Rose, C. H. Wouters, S. Meiorin et al. , "Pediatric granulomatous arthritis: an international registry, " Arthritis and Rheumatism, vol. 54, no. 10, pp. 3337-3344, 2006.
80. J. I. Arostegui, C. Arnal, R. Merino et al. , "NOD2 geneassociated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort, " Arthritis and Rheumatism, vol. 56, no. 11, pp. 3805-3813, 2007.
81. I. Okafuji, R. Nishikomori, N. Kanazawa et al. , "Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis, " Arthritis and Rheumatism, vol. 60, no. 1, pp. 242-250, 2009.
82. S. Manouvrier-Hanu, B. Puech, F. Piette et al. , "Blau syndrome of granulomatous arthritis, iritis, and skin rash: a new family and review of the literature, " The American Journal of Medical Genetics, vol. 76, no. 3, pp. 217-221, 1998.
83. S. A. Raphael, E. B. Blau, and S. H. Hsu, "Analysis of a large kindred with Blau syndrome for HLA, autoimmunity, and sarcoidosis, "The American Journal of Diseases of Children, vol. 147, no. 8, pp. 842-848, 1993.
84. P. A. Latkany, D. A. Jabs, J. R. Smithet al. , "Multifocal choroiditis in patients with familial juvenile systemic granulomatosis, " The AmericanJournal of Ophthalmology, vol. 134, no. 6, pp. 897-904, 2002.
85. T. Kurokawa, T. Kikuchi, K. Ohta, H. Imai, and N. Yoshimura, "Ocular manifestations in Blau syndrome associated with a CARD15/NOD2 mutation, " Ophthalmology, vol. 110, no. 10, pp. 2040-2044, 2003.
86. B. Snyers and K. Dahan, "Blau syndrome associated with a CARD15/NOD2 mutation, " The American Journal of Ophthalmology, vol. 142, no. 6, pp. 1089-1092, 2006.
87. S. K. Saini and C. D. Rose, "Liver involvement in familial granulomatous arthritis (Blau syndrome), " Journal of Rheumatology, vol. 23, no. 2, pp. 396-399, 1996.
88. S. See Ting, J. Ziegler, and E. Fischer, "Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions, " Journal of Pediatrics, vol. 133, no. 3, pp. 450-452, 1998.
89. L. Scerri, L. J. Cook, E. A. Jenkins, and A. L. Thomas, "Familial juvenile systemic granulomatosis (Blau's syndrome), " Clinical and ExperimentalDermatology, vol. 21, no. 6, pp. 445-448, 1996.
90. F. Mourad and A. Tang, "Sinus of valsalva aneurysm in Blau's syndrome, " Journal of Cardiothoracic Surgery, vol. 5, no. 1, article 16, 2010.
91. N. Milman, C. B. Andersen, A. Hansen et al. , "Favourable effect of TNF-α inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation, " APMIS, vol. 114, no. 12, pp. 912-919, 2006.
92. K. Yasui, M. Yashiro, M. Tsuge et al. , "Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/blau syndrome: its possible action and mechanism, " Arthritis and Rheumatism, vol. 62, no. 1, pp. 250-257, 2010.
93. S. T. Cliffe, J. M. Kramer, K. Hussain et al. , "SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway, " Human Molecular Genetics, vol. 18, no. 12, pp. 2257-2265, 2009.
94. I. Melki, K. Lambot, L. Jonard et al. , "Mutation in the SLC29A3 gene: a new cause of a monogenic, autoinflammatory condition, " Pediatrics, vol. 131, no. 4, pp. e1308-e1313, 2013.
95. S. Senniappan, M. Hughes, P. Shah, V. Shah, J. P. Kaski, P. Brogan et al. , "Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome is associated with severe chronic inflammation and cardiomyopathy, and represents a newmonogenic autoinflammatory syndrome, " Journal of Pediatric Endocrinology and Metabolism, vol. 26, no. 9-10, pp. 877-882, 2013.
96. K. Tanaka, "The proteasome: overview of structure and functions, " Proceedings of the Japan Academy B, vol. 85, no. 1, pp. 12-36, 2009.
97. H. J. Fehling, W. Swat, C. Laplace et al. , "MHC class I expression in mice lacking the proteasome subunit LMP-7, " Science, vol. 265, no. 5176, pp. 1234-1237, 1994.
98. M. Schmidt and D. Finley, "Regulation of proteasome activity in health and disease, " Biochimica et Biophysica Acta, vol. 1843, no. 1, pp. 13-25, 2014.
99. Y. Kitano, E. Matsunaga, T. Morimoto, N. Okada, and S. Sano, "A syndrome with nodular erythema, elongated and thickened fingers, and emaciation, " Archives of Dermatology, vol. 121, no. 8, pp. 1053-1056, 1985.
100. M. Tanaka, N. Miyatani, S. Yamada et al. , "Hereditary lipo-muscular atrophy with joint contracture, skin eruptions and hyper-gamma-globulinemia: a new syndrome, " Internal Medicine, vol. 32, no. 1, pp. 42-45, 1993.
101. S. Kasagi, S. Kawano, T. Nakazawa et al. , "A case of periodicfever-syndrome-like disorder with lipodystrophy, myositis, and autoimmune abnormalities, "Modern Rheumatology, vol. 18, no. 2, pp. 203-207, 2008.
102. A. Kitamura, Y. Maekawa, H. Uehara et al. , "A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans, " Journal of Clinical Investigation, vol. 121, no. 10, pp. 4150-4160, 2011.
103. A. Garg, M. D. Hernandez, A. B. Sousa et al. , "An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitis-associated lipodystrophy, " Journal of Clinical Endocrinology andMetabolism, vol. 95, no. 9, pp. E58-E63, 2010.
104. A. Megarbane, A. Sanders, E. Chouery, V. Delague, M. Medlej-Hashim, and P.-H. Torbey, "An unknown autoinflammatory syndrome associated with short stature and dysmorphic features in a young boy, " Journal of Rheumatology, vol. 29, no. 5, pp. 1084-1087, 2002.
105. A. Torrelo, S. Patel, I. Colmenero et al. , "Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, " Journal of the American Academy of Dermatology, vol. 62, no. 3, pp. 489-495, 2010.
106. Y. Ramot, T. Czarnowicki, A. Maly, P. Navon-Elkan, and A. Zlotogorski, "Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome: a case report, " Pediatric Dermatology, vol. 28, no. 5, pp. 538-541, 2011.
107. K. Oyanagi, K. Sasaki, E. Ohama et al. , "An autopsy case of a syndrome with muscular atrophy, decreased subcutaneous fat, skin eruption and hyper γ-globulinemia: peculiar vascular changes andmuscle fiber degeneration, " Acta Neuropathologica, vol. 73, no. 4, pp. 313-319, 1987.
108. N. Kanazawa, "Nakajo-Nishimura syndrome: an autoinflammatory disorder showing pernio-like rashes and progressive partial lipodystrophy, " Allergology International, vol. 61, no. 2, pp. 197-206, 2012.
109. K. Arima, A. Kinoshita, H. Mishima et al. , "Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 36, pp. 14914-14919, 2011.
110. A. K. Agarwal, C. Xing, G. N. Demartino et al. , "PSMB8 encoding the β5i proteasome subunit ismutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome, " The American Journal of Human Genetics, vol. 87, no. 6, pp. 866-872, 2010.
111. J. Kluk, M. Rustin, P. A. Brogan et al. , "CANDLE syndrome: a report of a novel mutation and review of the literature, " The British Journal of Dermatology, vol. 170, no. 1, pp. 215-217, 2014.
112. G. A. Montealegre Sanchez, A. L. Reinhardt, P. Brogan et al. , "Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE): clinical characterization and initial response to Janus kinase inhibition with baricitinib, " Arthritis and Rheumatology, vol. 65, no. 10, Supplement, ACR/ARHP Annual Meeting, abstract 1782, 2013.
113. N. G. Shoham, M. Centola, E. Mansfield et al. , "Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 23, pp. 13501-13506, 2003.
114. C. A. Wise, J. D. Gillum, C. E. Seidman et al. , "Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder, " Human Molecular Genetics, vol. 11, no. 8, pp. 961-969, 2002.
115. H. B. Yeon, N. M. Lindor, J. G. Seidman, and C. E. Seidman, "Pyogenic arthritis pyoderma gangrenosum, and acne syndrome maps to chromosome 15q, " The American Journal of Human Genetics, vol. 66, no. 4, pp. 1443-1448, 2000.
116. E. Cortis, F. De Benedetti, A. Insalaco et al. , "Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patientwith PAPAsyndrome, " Journal of Pediatrics, vol. 145, no. 6, pp. 851-855, 2004.
117. D. S. Stichweh, M. Punaro, and V. Pascual, "Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome, " Pediatric Dermatology, vol. 22, no. 3, pp. 262-265, 2005.
118. M. P. Dierselhuis, J. Frenkel, N. M. Wulffraat, and J. J. Boelens, "Anakinra for flares of pyogenic arthritis in PAPA syndrome, " Rheumatology, vol. 44, no. 3, pp. 406-408, 2005.
119. M. F. J. Andre, O. Aumaitre, G. Grateau et al. , "Longest form of CCTG microsatellite repeat in the promoter of the CD2BP1/PSTPIP1 gene is associated with aseptic abscesses and with crohn disease in French patients, " Digestive Diseases and Sciences, vol. 55, no. 6, pp. 1681-1688, 2010.
120. S. Reddy, S. Jia, R. Geoffrey et al. , "An autoinflammatory disease due to homozygous deletion of the IL1RN locus, " New England Journal of Medicine, vol. 360, no. 23, pp. 2438-2444, 2009.
121. I. Aksentijevich, S. L. Masters, P. J. Ferguson et al. , "An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist, " New England Journal ofMedicine, vol. 360, no. 23, pp. 2426-2437, 2009.
122. C. Schnellbacher, G. Ciocca, R. Menendez et al. , "Deficiency of interleukin-1 receptor antagonist responsive to anakinra, " Pediatric Dermatology, vol. 30, no. 6, pp. 758-760, 2013.
123. S. Marrakchi, P. Guigue, B. R. Renshaw et al. , "Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis, " New England Journal of Medicine, vol. 365, no. 7, pp. 620-628, 2011.
124. A. Onoufriadis, M. A. Simpson, A. E. Pink et al. , "Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis, " The American Journal ofHuman Genetics, vol. 89, no. 3, pp. 432-437, 2011.
125. L. Rossi-Semerano, M. Piram, C. Chiaverini, D. De Ricaud, A. Smahi, and I. Kone-Paut, "First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra, " Pediatrics, vol. 132, no. 4, pp. e1043-e1047, 2013.
126. H. A. Majeed, M. Kalaawi, D. Mohanty et al. , "Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings, " The Journal of Pediatrics, vol. 115, no. 5, pp. 730-734, 1989.
127. M. Valdearcos, E. Esquinas, C. Meana et al. , "Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages, " Journal of Biological Chemistry, vol. 287, no. 14, pp. 10894-10904, 2012.
128. Z. S. Al-Mosawi, K. K. Al-Saad, R. Ijadi-Maghsoodi, H. I. El-Shanti, and P. J. Ferguson, "A splice site mutation confirms the role of LPIN2 inMajeed syndrome, " Arthritis and Rheumatism, vol. 56, no. 3, pp. 960-964, 2007.
129. T. Herlin, B. Fiirgaard, M. Bjerre et al. , "Efficacy of anti-IL-1 treatment in Majeed syndrome, " Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 410-413, 2013.
130. A. Giedion, W. Holthusen, L. F. Masel, and D. Vischer, "Subacute and chronic "symmetrical" osteomyelitis, " Annales de Radiologie, vol. 15, no. 3, pp. 329-342, 1972.
131. E. Coinde, L. David, J. Cottalorda et al. , "Chronic recurrent multifocal osteomyelitis in children: a report of 17 cases, " Archives de Pediatrie, vol. 8, no. 6, pp. 577-583, 2001.
132. G. Khanna, T. S. P. Sato, and P. Ferguson, "Imaging of chronic recurrent Multifocal Osteomyelitis, " Radiographics, vol. 29, no. 4, pp. 1159-1177, 2009.
133. M. Hurtado-Nedelec, S. Chollet-Martin, D. Chapeton, J.-P. Hugot, G. Hayem, and B. Gerard, "Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes, " Journal of Rheumatology, vol. 37, no. 2, pp. 401-409, 2010.
134. C. Beck, H. J. Girschick, H. Morbach et al. , "Mutation screening of the IL-1 receptor antagonist gene in chronic non-bacterial osteomyelitis of childhood and adolescence, " Clinical and Experimental Rheumatology, vol. 29, no. 6, pp. 1040-1043, 2011.
135. J. C. Abril and A. Ramirez, "Successful treatment of chronic recurrentmultifocal osteomyelitis with indomethacin: a preliminary report of five cases, " Journal of Pediatric Orthopaedics, vol. 27, no. 5, pp. 587-591, 2007.
136. H. J. Girschick, C. Zimmer, G. Klaus, K. Darge, A. Dick, and H. Morbach, "Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated?" Nature Clinical Practice Rheumatology, vol. 3, no. 12, pp. 733-738, 2007.
137. C. Kerrison, J. E. Davidson, A. G. Cleary, and M. W. Beresford, "Pamidronate in the treatment of childhood SAPHO syndrome, " Rheumatology, vol. 43, no. 10, pp. 1246-1251, 2004.
138. P. M. H. Miettunen, X. Wei, D. Kaura, W. A. Reslan, A. N. Aguirre, and J. D. Kellner, "Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO), " Pediatric Rheumatology, vol. 7, article 2, 2009.
139. R. G. Marangoni and A. S. R. Halpern, "Chronic recurrent multifocal osteomyelitis primarily affecting the spine treated with Anti-TNF therapy, " Spine, vol. 35, no. 7, pp. E253-E256, 2010.